Palisade Bio Inc (PALI) Enters Exclusive Worldwide Licensing Agreement with Giiant Pharma for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Palisade Bio Inc.’s stock more than doubled in price on Wednesday, after the company announced a licensing agreement with privately held Giiant Pharma Inc..
– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND filing.